• +1-646-491-9876
    • +91-20-67278686

    Search

    Blepharitis - Pipeline Review, H1 2017

    Blepharitis - Pipeline Review, H1 2017

    • Report Code ID: RW0001709454
    • Category Pharmaceuticals
    • No. of Pages 54
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Blepharitis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Blepharitis - Pipeline Review, H1 2017, provides an overview of the Blepharitis (Ophthalmology) pipeline landscape.

    Blepharitis is an inflammation of the eyelids, usually caused by an excess growth of bacteria that is ordinarily found on the skin, blockage of the eyelid's oil glands, and occasionally allergies. Blepharitis signs and symptoms include watery eyes, red eyes, itchy eyelids, sensitivity to light. Treatment includes antibiotics, lubricating eye drops and steroid eye drops or ointments.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Blepharitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Blepharitis (Ophthalmology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Blepharitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 2 and 6 respectively.

    Blepharitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Blepharitis (Ophthalmology) .
    - The pipeline guide reviews pipeline therapeutics for Blepharitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Blepharitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Blepharitis (Ophthalmology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Blepharitis (Ophthalmology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Blepharitis (Ophthalmology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Blepharitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Blepharitis - Overview
    Blepharitis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Blepharitis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Blepharitis - Companies Involved in Therapeutics Development
    Allergan Plc
    Hovione FarmaCiencia SA
    InSite Vision Inc
    Kala Pharmaceuticals Inc
    Marinomed Biotechnologie GmbH
    Merck & Co Inc
    NicOx SA
    Quorum Innovations LLC
    Blepharitis - Drug Profiles
    AGN-195263 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    azithromycin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dexamethasone acetate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fluticasone propionate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ISV-405 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    loteprednol etabonate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Qi-402 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Blepharitis and Conjunctivitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    solithromycin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tetracycline - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Blepharitis - Dormant Projects
    Blepharitis - Product Development Milestones
    Featured News & Press Releases
    Jan 05, 2017: Nicox provides clinical and regulatory update for NCX 4251 in blepharitis
    Jul 08, 2014: InSite Vision Plans to Submit New Drug Application to FDA for DexaSiteâ„¢ for the Treatment of Blepharitis in Adults
    Nov 12, 2013: Kala Pharmaceuticals Presents Preclinical Data on Mucus Penetrating Particles at 2013 AAPS Annual Meeting and Exposition
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Blepharitis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Blepharitis - Pipeline by Allergan Plc, H1 2017
    Blepharitis - Pipeline by Hovione FarmaCiencia SA, H1 2017
    Blepharitis - Pipeline by InSite Vision Inc, H1 2017
    Blepharitis - Pipeline by Kala Pharmaceuticals Inc, H1 2017
    Blepharitis - Pipeline by Marinomed Biotechnologie GmbH, H1 2017
    Blepharitis - Pipeline by Merck & Co Inc, H1 2017
    Blepharitis - Pipeline by NicOx SA, H1 2017
    Blepharitis - Pipeline by Quorum Innovations LLC, H1 2017
    Blepharitis - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Blepharitis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Allergan Plc
    Hovione FarmaCiencia SA
    InSite Vision Inc
    Kala Pharmaceuticals Inc
    Marinomed Biotechnologie GmbH
    Merck & Co Inc
    NicOx SA
    Quorum Innovations LLC

    Request for Sample

    Report Url http://www.reportsweb.com//blepharitis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//blepharitis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//blepharitis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments